Overview
Mehri McKellar, MD is a Professor in the Division of Infectious Diseases at Duke University Medical Center, and has almost 20 years of experience in treating persons with HIV (PWH). She serves as one of the primary providers in the Duke ID Clinic.
Since her arrival at Duke University in 2008, one of her major research interests has been on HIV prevention – including rapid HIV testing in non-traditional settings such as emergency rooms and in the community, and more recently, pre-exposure prophylaxis (PrEP). She serves as the Medical Director of the Duke PrEP clinic, which was the first dedicated PrEP Clinic in North Carolina and has seen >500 persons for HIV prevention. Her work with PrEP also extends to persons who inject drugs via syringe services programs and to individuals who are incarcerated.
Current Appointments & Affiliations
Recent Publications
Lyme Neuroborreliosis With Acute Encephalopathy Despite Early Antibiotic Therapy: A Case Report.
Journal Article Am J Case Rep · April 6, 2026 BACKGROUND Lyme disease is a tick-borne infection caused by spirochetes of the Borrelia burgdorferi sensu lato species complex (Bb). Lyme neuroborreliosis occurs in up to 15% of untreated Lyme disease cases and most commonly presents with painful radiculit ... Full text Link to item CiteCOMPARATIVE SAFETY OF B/F/TAF VS. OTHER ANTIRETROVIRAL THERAPY REGIMENS FOR TREATMENT EXPERIENCED PEOPLE WITH HIV-1: A SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS USING MULTILEVEL NETWORK META-REGRESSION
Conference VALUE IN HEALTH · December 2025 Link to item CiteOpinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users.
Journal Article AIDS Behav · October 2025 Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) has potential to increase PrEP uptake and adherence. However, most studies investigating opinions about LAI PrEP were done prior to its approval. We administered a cross-sectional electronic surv ... Full text Link to item CiteRecent Grants
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2024 - 2030ISLEND-1 A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2024 - 2030Interdisciplinary Research Training Program in AIDS
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2030View All Grants